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TO THE EDITOR: As members of the International Society for
Pharmacoeconomics and Outcomes Research, we read with great
interest the new American Society of Clinical Oncology (ASCO)
conceptual framework to assess the value of cancer treatment
options.1 We applaud the Value in Cancer Care Task Force for
proposing a conceptual framework to support clinicians and pa-
tients in assessing the value of new cancer treatments. We ac-
knowledge the challenges facing clinician–patient decision making,
particularly concerning cancer treatments. Like ASCO, we rec-
ognize that the cost of treatments is increasingly being placed on
patients through cost sharing and that engaging patients as part of
making individual treatment decisions is of high importance. The
ASCO framework highlights the growing tension among patients,
insurance companies, and productmanufacturers in a dynamic health
care environment. In that light, the framework deserves a ﬁeld test,
andwe look forward to seeing the outcome of that experience.We also
appreciate the opportunity to offer comments and suggestions on the
ASCO framework at this early stage, and our membership stands
ready to support ASCO in future enhancements.
In our view, the proposed framework focusing on the
patient–physician dyad is an interesting approach and has some
desirable elements, but also some important limitations. It would
be helpful to clarify differences between a value framework to
support physician–patient individual-level decision making and
a framework that would operate more at a broader societal level.
Indeed, the two perspectives are linked in that decisions made at
the individual level, when aggregated, affect the resources avail-
able to the health care system, the overall cost of health care, and,
ultimately, access and health outcomes that can be delivered to
all patients. This reﬂects the need for health systems to consi-
der cost effectiveness appropriately in decisions about funding,
pricing, and reimbursement. The European Society of Medical
Oncology, for example, created the Magnitude of Clinical Beneﬁt
Scale in an effort similar to that of the ASCO task force, but
that approach takes into account whether beneﬁt is curative or
palliative and only applies to solid tumor types.2 Furthermore,
validated measures of health-related quality of life are explicitly
incorporated into the European Society of Medical Oncology
approach.
Although the focus of the ASCO value framework is on the
patient perspective, the article also notes that the physician “has a
responsibility to be a good steward of health care resources.”1(p2564)
Clinical treatment guidelines that consider cost effectiveness and
reﬂect differing health state valuations among patients can provide
clinicians with a way to help resolve what might seem to be a conﬂict
in these roles. We encourage ASCO to consider expanding its
perspective, giving consideration to this broader framework when
developing treatment guidelines.
Such an approach would be consonant with recent recom-
mendations by the American College of Cardiology/American
Heart Association to incorporate cost-effectiveness analysis into
clinical treatment guideline development.3 Patients with serious
cardiac disease face many of the same issues that patients with
cancer face: severe limitations in functional status and quality of
life, high mortality, and burden of treatment.
In its conceptual framework, the task force did not embrace
the use of quality-adjusted life-years (QALYs). The authors noted
concerns that the QALY may not fully capture all of the relevant
attributes sufﬁciently, that there is no consensus on thresholds for
incremental cost-effectiveness ratios, and that so-called health care
rationing is implied. Althoughwe recognize these points, the health
economics and outcomes research ﬁeld is substantially invested in
using both QALYs and cost-effectiveness analyses as tools to
support the difﬁcult health care resource allocation decisions
that societies face. For example, the Tufts Medical Center Cost-
Effectiveness Analysis Registry4 catalogs more than 4,300 cost-
utility analyses with valuations of patient health-related quality
of life in more than 10,000 health states. We recognize that the
direct usefulness of these tools for individual patients may be
limited; however, we have suggestions concerning the deﬁnition
of value criteria and the methods used to derive the weights and
the resulting outcomes in the ASCO value framework. We would
encourage that future research engage experts in multicriteria
decision analysis to validate and revise the weights and, if
necessary, incorporate individual patient preferences into the
framework.
In summary, we applaud the efforts by ASCO to incorporate
value assessments in an environment of constrained resources. As
a leading society of health economists and outcomes researchers,
the International Society for Pharmacoeconomics and Outcomes
Research has developed more than 40 good practice guidelines
related to health technology assessment. We invite ASCO and other
societies to engage our members in the creation and validation of
value assessment tools.
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NOTE. The authors of the ASCO value framework have addressed
these as well as other comments in the accompanying Special
Article entitled “Updating the American Society of Clinical
Oncology Value Framework: Revisions and Reﬂections in Re-
sponse to Comments Received.”5
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